January 25, 2013
Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, January 25, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced the addition of Dr. Neil M. Barth as its Chief Medical Officer. In this role, Dr. Barth will translate complex laboratory science and personalized medicine diagnostics into actionable, patient centered solutions for clinicians.
Dr. Barth is a highly skilled physician with 35 years of collective experience with innovative care delivery and genomic biomarker development. His tenure of leadership at Hoag Hospital, in Newport Beach, CA provided him a rich opportunity to lead a medical staff of 1,400 physicians and 4,400 nurses. With a strong background in the basic sciences, health informatics, clinical and regulatory standards, combined with the requisite business acumen, Dr. Barth has been at the forefront transforming the practice and business of medicine in several key areas. Dr. Barth is board certified in Internal Medicine, Hematology and Medical Oncology. In addition to his medical background, he is a prolific author and co-author and a noted speaker, facilitator, moderator and presenter for a vast array of healthcare management and clinical forums.
“As we enter our next phase of expansion, we are thrilled to add Dr. Barth to our executive team,” said David Macdonald, Agendia’s Chief Executive Officer. “Dr. Barth’s wealth of experience will guide our efforts as we continue to develop Agendia’s rich product pipeline to answer key clinical questions for physicians.”
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient’s individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials. For more information, please visit www.agendia.com.
For further information, please contact:
Allen & Caron Inc.